Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 4/20 | 0.50 |
| ▸ | SSTR2 | P30874 | 3/20 | 0.50 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.50 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.50 |
| ▸ | DDOST | P39656 | 1/20 | 0.48 |
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.47 |
| ▸ | OXTR | P30559 | 1/20 | 0.47 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | CD2 | P06729 | 1/20 | 0.43 |
| ▸ | CD58 | P19256 | 1/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26814255 | 0.89 | SSTR2 (0.54) | SSTR5SSTR2SSTR1SSTR3UTS2R | |
| SCHEMBL20963290 | 0.88 | SSTR2 (0.48) | SSTR5SSTR2SSTR1SSTR3UTS2R | |
| SCHEMBL19543950 | 0.79 | SSTR2 (0.61) | SSTR5SSTR2SSTR1SSTR3 | |
| SCHEMBL18712329 | 0.78 | SSTR2 (0.61) | SSTR5SSTR2SSTR1SSTR3 | |
| SCHEMBL20465864 | 0.78 | CACNA1B (0.50) | SSTR5SSTR2SSTR1SSTR3OXTR | |
| SCHEMBL21312758 | 0.77 | OXTR (0.58) | SSTR5SSTR2SSTR1SSTR3OXTR | |
| SCHEMBL22844368 | 0.77 | OXTR (0.58) | SSTR5SSTR2SSTR1SSTR3OXTR | |
| SCHEMBL18712893 | 0.77 | SSTR2 (0.70) | SSTR5SSTR2SSTR1SSTR3 | |
| SCHEMBL23968131 | 0.76 | OXTR (0.59) | SSTR5SSTR2OXTRSRCCD2 | |
| SCHEMBL22891909 | 0.76 | OXTR (0.59) | SSTR5SSTR2OXTRSRCCD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9750818-B2 | Targeted conjugates and particles and formulations thereof | TARVEDA THERAPEUTICS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170095569-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2017-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170095569-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | SSTR5, SSTR1, SSTR4 | SSTR5 1/4885SSTR2 4/4885SSTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.